Ann Marie K. Weideman

Ann Marie K. Weideman

Auto-generated profile, based on publicly available information

Ann Marie K. Weideman

Department of Biostatistics The University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2022 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
CWCheng Wang
Cheng Wang
JOJason J. Ong
Jason J. Ong
PZPeizhen Zhao
Peizhen Zhao
AWAnn Marie Weideman
Ann Marie Weideman
Weiming TangWeiming Tang
Weiming Tang
BYBin Yang
Bin Yang
Background: Low syphilis testing uptake is a major public health issue among men who have sex with men (MSM) in many low- and middle-income countries. Syphilis self-testing (SST) may complement and extend facility-based testing. We aimed to evaluate the effectiveness and costs of providing SST on increasing syphilis testing uptake among MSM in China. Methods and findings: An open-label, parallel 3-arm randomized controlled trial (RCT) was conducted between January 7, 2020 and July 17, 2020. Men who were at least 18 years of age, had condomless anal sex with men in the past year, reported not testing for syphilis in the last 6 months, and had a stable residence with mailing addresses were recruited from 124 cities in 26 Chinese provinces. Using block randomization with blocks of size 12, enrolled participants were randomly assigned (1:1:1) into 3 arms: standard of care arm, standard SST arm, and lottery incentivized SST arm (1 in 10 chance to win US$15 if they had a syphilis test). The primary outcome was the proportion of participants who tested for syphilis during the trial period and confirmed with photo verification and between arm comparisons were estimated with risk differences (RDs). Analyses were performed on a modified intention-to-treat basis: Participants were included in the complete case analysis if they had initiated at least 1 follow-up survey. The Syphilis/HIV Duo rapid test kit was used. A total of 451 men were enrolled. In total, 136 (90·7%, 136/150) in the standard of care arm, 142 (94·0%, 142/151) in the standard of SST arm, and 137 (91·3%, 137/150) in the lottery incentivized SST arm were included in the final analysis. The proportion of men who had at least 1 syphilis test during the trial period was 63.4% (95% confidence interval [CI]: 55.5% to 71.3%, p = 0.001) in the standard SST arm, 65.7% (95% CI: 57.7% to 73.6%, p = 0.0002) in the lottery incentivized SST arm, and 14.7% (95% CI: 8.8% to 20.7%, p < 0.001) in the standard of care arm. The estimated RD between the standard SST and standard of care arm was 48.7% (95% CI: 37.8% to 58.4%, p < 0.001). The majority (78.5%, 95% CI: 72.7% to 84.4%, p < 0.001) of syphilis self-testers reported never testing for syphilis. The cost per person tested was US$26.55 for standard SST, US$28.09 for the lottery incentivized SST, and US$66.19 for the standard of care. No study-related adverse events were reported during the study duration. Limitation was that the impact of the Coronavirus Disease 2019 (COVID-19) restrictions may have accentuated demand for decentralized testing. Conclusions: Compared to standard of care, providing SST significantly increased the proportion of MSM testing for syphilis in China and was cheaper (per person tested). Trial registration: Chinese Clinical Trial Registry: ChiCTR1900022409.

8 January 2025 in Statistics in Biosciences
Verified
Journal Article
Open access
PDF file
AWAnn Marie K. Weideman
Ann Marie K. Weideman
RWRujin Wang
Rujin Wang
JIJoseph G. Ibrahim
Joseph G. Ibrahim
YJYuchao Jiang
Yuchao Jiang
Tumors are comprised of a mixture of distinct cell populations that differ in terms of genetic makeup and function. Such heterogeneity plays a role in the development of drug resistance and the ineffectiveness of targeted cancer therapies. Insight into this complexity can be obtained through the construction of a phylogenetic tree, which illustrates the evolutionary lineage of tumor cells as they acquire mutations over time. We propose Canopy2, a Bayesian framework that uses single nucleotide variants derived from bulk DNA and single-cell RNA sequencing to infer tumor phylogeny and conduct mutational profiling of tumor subpopulations. Canopy2 uses Markov chain Monte Carlo methods to sample from a joint probability distribution involving a mixture of binomial and beta-binomial distributions, specifically chosen to account for the sparsity and stochasticity of the single-cell data. Canopy2 demystifies the sources of zeros in the single-cell data and separates zeros categorized as non-cancerous (cells without mutations), stochastic (mutations not expressed due to bursting), and technical (expressed mutations not picked up by sequencing). Simulations demonstrate that Canopy2 consistently outperforms competing methods and reconstructs the clonal tree with high fidelity, even in situations involving low sequencing depth, poor single-cell yield, and highly-advanced and polyclonal tumors. We further assess the performance of Canopy2 through application to breast cancer and glioblastoma data, benchmarking against existing methods. Canopy2 is an open-source package available at https://github.com/annweideman/canopy2 .

19 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
AWAnn Marie K. Weideman
Ann Marie K. Weideman
RWRujin Wang
Rujin Wang
JIJoseph G. Ibrahim
Joseph G. Ibrahim
YJYuchao Jiang
Yuchao Jiang
Tumors are comprised of a mixture of distinct cell populations that differ in terms of genetic makeup and function. Such heterogeneity plays a role in the development of drug resistance and the ineffectiveness of targeted cancer therapies. Insight into this complexity can be obtained through the construction of a phylogenetic tree, which illustrates the evolutionary lineage of tumor cells as they acquire mutations over time. We propose Canopy2, a Bayesian framework that uses single nucleotide variants derived from bulk DNA and single-cell RNA sequencing to infer tumor phylogeny and conduct mutational profiling of tumor subpopulations. Canopy2 uses Markov chain Monte Carlo methods to sample from a joint probability distribution involving a mixture of binomial and beta-binomial distributions, specifically chosen to account for the sparsity and stochasticity of the single-cell data. Canopy2 demystifies the sources of zeros in the single-cell data and separates zeros categorized as non-cancerous (cells without mutations), stochastic (mutations not expressed due to bursting), and technical (expressed mutations not picked up by sequencing). Simulations demonstrate that Canopy2 consistently outperforms competing methods and reconstructs the clonal tree with high fidelity, even in situations involving low sequencing depth, poor single-cell yield, and highly-advanced and polyclonal tumors. We further assess the performance of Canopy2 through application to breast cancer and glioblastoma data, benchmarking against existing methods. Canopy2 is an open-source R package available at https://github.com/annweideman/canopy2 .

1 March 2025 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
ADAaron S. Devanathan
Aaron S. Devanathan
APAmanda J. Bs Poliseno
Amanda J. Bs Poliseno
NWNicole R. White
Nicole R. White
ASAmanda Panty Schauer
Amanda Panty Schauer
CSCraig Sykes
Craig Sykes
MCMackenzie L Cottrell
Mackenzie L Cottrell
Background: Incomplete adherence to daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) reduces effectiveness. Adherence biomeasures (ie, drug concentrations in biological specimen) are more accurate than self-report. TDF/FTC's intracellular active metabolites (tenofovir-diphosphate; TFVdp and FTC-triphosphate; FTCtp) can be quantified in different types of blood samples to estimate adherence. To optimize adherence estimation, we investigated approaches to measure TFVdp and FTCtp in 4 blood matrices. Methods: Twelve HIV-negative, healthy volunteers were enrolled in a single-center, open-label, 3-phase, directly observed therapy study. LC-MS/MS methods quantified TFVdp/FTCtp in dried blood spots, volumetrically accurate microsampling, upper layer packed cells, and peripheral blood mononuclear cells (PBMCs). Noncompartmental analysis estimated half-lives and accumulation ratios. Correlations characterized relationships between clinical variables and exposure. Regression models were fit to determine concentrations associated with <4 and ≥4 doses/week; correct classification percentages were determined. Results: Terminal half-life estimates of 3–4 vs 15–22 days distinguished between moderate-term (FTCtp in all samples; TFVdp in PBMCs) versus long-term (TFVdp in red blood cell–containing matrices) measures. Model-derived thresholds accurately categorized <4 and ≥4 doses/week when including both metabolites for 14- and 28-day dosing periods (81%–91% and 82%–85%, respectively). Within each classification and regression trees analyses containing both moderate- and long-term measures, dried blood spots exhibited highest accuracy to predict stable (74%–94%) and changing (42%–47%) adherence patterns. Conclusions: We demonstrate higher accuracy of moderate-term biomeasures to classify adherence over a 14-day period compared with long-term biomeasures to classify adherence over a 28-day period. Combined moderate- and long-term biomeasures predicted stable and changing adherence patterns, with dried blood spots exhibiting highest accuracy.

14 August 2024 in Journal of Statistical Research
Verified
Journal Article
Open access
PDF file
AWAnn Marie K Weideman
Ann Marie K Weideman
EKElaine K Kowalewski
Elaine K Kowalewski
GKGary G Koch
Gary G Koch
In many randomized multi-visit studies, some response variables have an ordinal scale for outcomes. The win odds (accounts for ties) and the win ratio (ignores ties) are useful for treatment comparisons for ordinal outcomes. This paper discusses the application of randomization-based covariance and stratification adjustment of the win odds (and win ratio) to enable their more convenient use. Adjustment for strata is through the weighted average of within stratum two-sample U statistics for numerators and denominators for the stratified win odds (or win ratio). As randomization-based, invocation of covariance adjustment is through constraints to zeros for baseline covariate differences in the joint vector with logarithms of stratified win odds (or win ratios) for the respective visits. Such adjustment has no formal assumptions about the distributions of response variables or co-variates or the relationships of covariates to response variables; but the resulting adjusted stratified win odds (or win ratios) have narrower confidence intervals than their unadjusted counterparts when covariates have at least moderately strong associations with response variables. There is illustration of such results for the stratified win odds (and win ratio) for a randomized multi-visit clinical trial with an ordinal outcome for a chronic respiratory disorder. Journal of Statistical Research 2024, Vol. 58, No. 1, pp. 33-48

4 August 2022 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
CWCheng Wang
Cheng Wang
JOJason J. Ong
Jason J. Ong
PZPeizhen Zhao
Peizhen Zhao
AWAnn Marie Weideman
Ann Marie Weideman
Weiming TangWeiming Tang
Weiming Tang
BYBin Yang
Bin Yang
[This corrects the article DOI: 10.1371/journal.pmed.1003930.].